Renold, STV Group And Argent BioPharma
Mark Watson-Mitchell checks in on a set of shares that show some promise.
Mark Watson-Mitchell checks in on a set of shares that show some promise.
After such a strong upward push in UK equities of late, it is only a natural question considered by many investors – is it right this year to sell in May and go away?
A comment on recent coverage as well as a look at Mears, Wilmington and more.
Mark Watson-Mitchell provides readers with updates about two shares with very different prospects.
Mark Watson-Mitchell checks back in on two old favourites.
Mark Watson-Mitchell takes a closer look at this geospatial software specialist.
Mark Watson-Mitchell focuses in on some shares that he’s covered in the past.
Mark Watson-Mitchell revisits a selection of his previously profiled equities.
Does it have to take a former Chairman of the US Federal Reserve, Ben Bernanke, to tell us that the Governor and his colleagues have been unable to properly predict the ensuing economic shocks after Russia invaded Ukraine?
Mark Watson-MItchell checks up on the latest stories from some of his favourite small cap shares.